ArticleFrontiers in microbiology2025
A plasma proteomic signature of the actin-coagulation axis accurately predicts progression to active tuberculosis.
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Predicting progression to active tuberculosis (TB) is a critical unmet need, as current immunological tests only detect infection but cannot discriminate those who will develop active disease. A reliable prognostic biomarker could enable targeted preventive therapy and transform TB control strategies. Methods: We performed deep plasma proteomics using data-independent acquisition mass spectrometry on a prospective cohort of 60 TB-exposed students in Jiangsu Province, China, comprising 40 individuals with Results: Over 2 years of follow-up, 21 of the 40 infected participants progressed to active disease, and a LASSO-Cox model with internal cross-validation for tuning the regularization parameter ( Conclusion: We identified a plasma protein signature that accurately predicts progression from latent to active tuberculosis, linking disease onset to dysregulation of the actin cytoskeleton and coagulation. This biomarker provides a basis for precision preventive therapy and identifies novel host-directed therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.